Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT05339321 Recruiting - Clinical trials for Hepatocellular Carcinoma

Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC

Start date: April 14, 2021
Phase: Phase 1
Study type: Interventional

Adoptive cell therapy with TCR-T cells targeting HBV antigens represents an innovative opportunity for treatment of HBV-related HCC. SCG101 is a genetically modified autologous TCR-T cell therapy with a natural high-avidity TCR directed towards the HLA-A*02-restricted HBsAg peptide. This is a phase 1 clinical study of SCG101 alone and with PD-1/PD-L1 checkpoint inhibitors in HBV-related HCC.

NCT ID: NCT05337137 Recruiting - Clinical trials for Carcinoma, Hepatocellular

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

RELATIVITY-106
Start date: May 5, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).

NCT ID: NCT05332821 Recruiting - Clinical trials for Hepatocellular Carcinoma

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC

CHANCE2201
Start date: December 28, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage hepatocellular carcinoma (HCC).

NCT ID: NCT05332496 Recruiting - Clinical trials for Hepatocellular Carcinoma

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC

CHANCE2202
Start date: December 28, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with PD-1/PD-L1 Inhibitors and molecular target therapies in patients with Intermediate-stage hepatocellular carcinoma (HCC).

NCT ID: NCT05331911 Recruiting - Clinical trials for Hepatocellular Carcinoma

Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors

Start date: April 26, 2022
Phase: Phase 4
Study type: Interventional

This is a two-arm, parallel-group randomized clinical trial. Routine perioperative care would be performed in volunteers with primary Hepatocellular carcinoma. The study will enroll approximately 500 volunteers to compare the progression-free or overall survival in patients undergoing elective partial hepatectomy for primary liver tumors between propofol and sevoflurane for the maintenance of anesthesia.

NCT ID: NCT05323201 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Start date: February 10, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in treating hepatocellular carcinoma.

NCT ID: NCT05320692 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

Start date: August 9, 2022
Phase: Phase 3
Study type: Interventional

A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.

NCT ID: NCT05319431 Recruiting - Clinical trials for Unresectable, Non-metastatic Hepatocellular Carcinoma

A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC

Start date: June 28, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of AK104 plus lenvatinib combined with on-demand TACE in participants with unresectable, non-metastatic hepatocellular carcinoma

NCT ID: NCT05317819 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Start date: March 14, 2022
Phase: Phase 3
Study type: Interventional

Evaluate efficacy and safety of ADI-PEG 20 in patients with high-argininephenotypic and HCC

NCT ID: NCT05313282 Recruiting - Clinical trials for C-staged Hepatocellular Carcinoma in BCLC Classification

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification

TRIPLET-III
Start date: June 15, 2022
Phase: Phase 3
Study type: Interventional

This study was designed to evaluate the effectiveness and safety of hepatic arterial infusion chemotherapy combined with Apatinib and Camrelizumab (treatment group) versus Apatinib and Camrelizumab (control group) for C-staged Hepatocellular Carcinoma in BCLC classification. The primary outcome measure is to evaluate the progression-free-survival (PFS) of treatment group and control group for C-staged Hepatocellular Carcinoma in BCLC classification. The secondary Outcome measures include the overall survival (OS), time to progress (TTP), time-to-response (TTR), duration of response (DOR), objective response rate (ORR) and disease control rate (DCR) of treatment group and control group for C-staged Hepatocellular Carcinoma in BCLC classification. Moreover, this study aims to assess the safety and tolerability of treatment group and control group for C-staged Hepatocellular Carcinoma in BCLC classification.